SOLIFENACIN SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
When do Solifenacin Succinate patents expire, and what generic alternatives are available?
Solifenacin Succinate is a drug marketed by Accord Hlthcare, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Annora Pharma, Aurobindo Pharma, Austarpharma, Breckenridge, Chartwell Rx, Cipla, Glenmark Speclt, Lannett Co Inc, Macleods Pharms Ltd, MSN, Qilu, Rising, Sciegen Pharms Inc, Strides Pharma, Sunshine, Teva Pharms Usa, Unichem, Watson Labs Inc, and Zydus Pharms. and is included in twenty-four NDAs.
The generic ingredient in SOLIFENACIN SUCCINATE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Solifenacin Succinate
A generic version of SOLIFENACIN SUCCINATE was approved as solifenacin succinate by TEVA PHARMS USA on April 2nd, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SOLIFENACIN SUCCINATE?
- What are the global sales for SOLIFENACIN SUCCINATE?
- What is Average Wholesale Price for SOLIFENACIN SUCCINATE?
Summary for SOLIFENACIN SUCCINATE
Recent Clinical Trials for SOLIFENACIN SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Longhua Hospital | N/A |
| Shanghai University of Traditional Chinese Medicine | N/A |
| Genuine Research Center, Egypt | Phase 1 |
Pharmacology for SOLIFENACIN SUCCINATE
| Drug Class | Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Medical Subject Heading (MeSH) Categories for SOLIFENACIN SUCCINATE
Anatomical Therapeutic Chemical (ATC) Classes for SOLIFENACIN SUCCINATE
Paragraph IV (Patent) Challenges for SOLIFENACIN SUCCINATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VESICARE LS | Oral Suspension | solifenacin succinate | 1 mg/mL | 209529 | 1 | 2021-05-27 |
| VESICARE | Tablets | solifenacin succinate | 5 mg and 10 mg | 021518 | 1 | 2009-04-08 |
US Patents and Regulatory Information for SOLIFENACIN SUCCINATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 091464-001 | Apr 2, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Qilu | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 209333-002 | May 20, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Watson Labs Inc | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 202551-001 | May 20, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
